Overview

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

Status:
Withdrawn

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.

Phase:

Phase 2

Details

Lead Sponsor:

Celator Pharmaceuticals
Jazz Pharmaceuticals

Treatments:

Cytarabine
Daunorubicin